Amgen Reports meta-analysis Data for Semaglutide in Acute myeloid leukemia

Amgen today announced meta-analysis results for Semaglutide in patients with Acute myeloid leukemia. The study demonstrated that Semaglutide reduces biomarker levels substantially compared to standard of care or placebo. These results provide important insights into the treatment of Acute myeloid leukemia and support the continued development of Semaglutide in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Semaglutide was consistent with previous observations, with no new safety signals identified.